SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Valiant Laboratories Ltd

BSE: 543998 NSE: VALIANTLAB ISIN: INE0JWS01017
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Valiant Laboratories Ltd belong to?
Valiant Laboratories Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Valiant Laboratories Ltd a good quality company?
Valiant Laboratories Ltd is a weak quality company, based on a inconsistent 10 year financial track record.
Q.3 Is Valiant Laboratories Ltd undervalued or overvalued?
Valiant Laboratories Ltd appears Somewhat Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Valiant Laboratories Ltd a good buy now?
Valiant Laboratories Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Valiant Laboratories Ltd?
Valiant Laboratories Ltd revenue growth is -26.8% for FY-2025 , which is below its 5 year CAGR of 0% , indicating slower growth.
Q.2 Gross Profit margin of Valiant Laboratories Ltd?
Valiant Laboratories Ltd Gross profit margin which is the profit after deduction of direct costs, is 0.4% for FY-2025 , which is below its 5 year median of 7.95% , indicating decreasing margins.
Q.3 Operating Profit Margin of Valiant Laboratories Ltd?
Valiant Laboratories Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -1.07% for FY-2025 , which is below its 5 year median of 6.73% indicating decreasing margins.
Q.4 Net Profit Margin of Valiant Laboratories Ltd?
Valiant Laboratories Ltd Net Profit Margin is -1.61% for FY-2025 , is below with its 5 year median of 4.81%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 0.4 7.95
Operating Profit Margin -1.07 6.73
Net Profit Margin -1.61 4.81
Q.5 Return on Asset of Valiant Laboratories Ltd?
Valiant Laboratories Ltd Return on Asset is -0.67%, which is below its 5 year historical median of 7.63%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Valiant Laboratories Ltd?
Valiant Laboratories Ltd Return on equity is -0.91% for FY-2025 , which is below its historical median of 19.34%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Valiant Laboratories Ltd?
Valiant Laboratories Ltd Return on capital employed is -0.43% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Valiant Laboratories Ltd?
Valiant Laboratories Ltd Cash conversion cycle is 120 days, above its historical median of 94 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.42 1.19
ROE -0.91 19.34
ROCE -0.43 15.66
Cash Conversion Cycle 120 days 94 days
Q.9 Debt to Equity ratio of Valiant Laboratories Ltd?
Valiant Laboratories Ltd Debt-to-Equity ratio is 0.25 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of Valiant Laboratories Ltd?
Valiant Laboratories Ltd Debt to cash flow from operations is -2.71 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Valiant Laboratories Ltd?
Promoters hold 74.94% of the Valiant Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Valiant Laboratories Ltd vs industry peers?
Valiant Laboratories Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 133.4 137.1
Gross Profit 0.5 15.1
Operating Profit -5 16
Net Profit -2 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.42 0.8
ROE -0.91 8.91
ROCE -0.43 11.59
Cash Conversion Cycle (days) 119.64 76

Valuation & price assessment

Q.1 Stock return of Valiant Laboratories Ltd over the last decade?
Over the last 1 year(s), the stock has delivered a CAGR of -22.16% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - - -22.2%
Q.3 Valuation ratios of Valiant Laboratories Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 69.28 0.00 40.28
Price to Book 1.15 2.19 2.77
Price to Sales 1.74 3.46 2.65
EV to EBITDA 37.16 0.00 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×